Pivotal clinical studies like SOLO-1 and PAOLA-1 investigating PARP inhibitor treatment of ovarian cancer patients used the same PARPi doses and did not investigate the effect of different dosing, nor did they correlate markers of STING activation with therapy response [3, 50]. Here, PARP1 is linked to ovarian cancer.